Fig. 3.
Hepatic activation of FOXO3 supports hepatotoxicity-mediated tumorigenesis. a Representative IHC staining for FOXO3 in 40-week-old DEN-injected control and DEN-injected FOXO3CAHep transgenic mice (bar = 100 μm). b Western blot analysis in livers from 40-week-old DEN-injected control and DEN-injected FOXO3CAHep transgenic mice with FOXO3 and GAPDH as loading control (lower panel), as well as densitometric quantification (upper panel). c Macroscopic appearance of livers in DEN-injected control and FOXO3CAHep transgenic 40-week-old mice (bar = 1 cm). d Body weight and liver weight of 40-week-old control, FOXO3CAHep, DEN-injected control and DEN-injected FOXO3CAHep transgenic mice (control and FOXO3CAHep n = 3, DEN-injected control and DEN-injected FOXO3CAHep, n = 5). e Representative hematoxylin and eosin and IHC staining for Collagen IV (bar = 100 μm). f Representative MRI imaging of livers from DEN-injected control and DEN-injected FOXO3CAHep transgenic mice. g Tumor numbers, incidence and volume in livers from DEN-injected control (n = 6) and DEN-injected FOXO3CAHep transgenic mice (n = 5). h Alanine aminotransferase levels in 40-week-old FOXO3CAHep control, FOXO3CAHep, DEN-injected control and DEN-injected FOXO3CAHep transgenic mice (n = 3)